Optimal management of Cushing syndrome

References

• Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A. Cushing’s syndrome. EndocrinolMetab Clin NAm. 2008;37(1):135–149.
   Web of Science ®Google Scholar
• Espinosa de los Monteros-Sánchez AL, Valdivia-López J, Mendoza-Zubieta V Mercado-Atri M, Gómez-Pérez F, Romero-Zazueta A, et al. Consenso en el diagnóstico y tratamiento del síndrome de Cushing. Rev Endocrinol Nutr. 2007;15(4):S3-S12.
   Google Scholar
• Lindholm J, Jull SJ, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. Clin Endocrinol Metab. 2001;86:117–123.
   Google Scholar
• Curtis JR, Westfall AO, Allison J, Bijlsma JM, Freeman A, George V et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420–426.
   PubMed Web of Science ®Google Scholar
• McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008;20(2):131–137.
   PubMed Web of Science ®Google Scholar
• Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet. 2006;367(9522):1605–1617.
   PubMed Web of Science ®Google Scholar
• Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab. 2003;88(12):5808–5813.
   Web of Science ®Google Scholar
• Isidori AM, Kaltsas GA, Pozza C, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management and long-term follow-up. J Clin Endocrinol Metab. 2006;91(2):371–377.
   PubMed Web of Science ®Google Scholar
• Boscaro M, Barzon L, Fallo F, Sonino N. Cushing’s syndrome. Lancet. 2001;357(9258):783–791.
   PubMed Web of Science ®Google Scholar
• Pivonello R, Faggiano A, Lombardi G, Colao A. The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol Metab Clin North Am. 2005;34(2):327–339.
   PubMed Web of Science ®Google Scholar
• Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526–1540.
   PubMed Web of Science ®Google Scholar
• González Albarrán O, García-Robles R. Síndrome de Cushing. Medicine. 2000;8:1102–1111.
   Google Scholar
• Axelrod L. Glucocorticoid therapy. Medicine. 1976;56:39–65.
   Google Scholar
• Livanou T, Ferriman D, James VH. Recovery of hypothalamo-pituitary- adrenal function after corticosteroid therapy. Lancet. 1967;2(7521):856–859.
   Web of Science ®Google Scholar
• Robinson BH, Mattingly D, Cope CL. Adrenal function after prolonged corticosteroid therapy. Br Med J. 1962;1(5292):1579–1584.
   Google Scholar
• LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med. 1993;95(3):258–264.
   PubMed Web of Science ®Google Scholar
• Pérez EG, Hernández EA, Zuñiga AE, et al. Comparison of the severity index in Cushing’s syndrome between patients with endogenous and iatrogenic disease. Endocrinol Nutr. 2010;57(9):426–433.
   Google Scholar
• Richter B, Neises G, Clar C. Glucocorticoid withdrawal schemes in chronic medical disorders. A systematic review. Endocrinol Metab Clin North Am. 2002;31(3):751–778.
   Web of Science ®Google Scholar
• Hopkins RL, Leinung MC. Exogenous Cushing’s syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin North Am. 2005;34(2):371–384.
   PubMed Web of Science ®Google Scholar
• Axelrod L. Corticosteroid therapy. Principles and Practice of Endocrinology and Metabolism. Becker KL, ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001:751–764.
   Google Scholar
• Mantero F, Scaroni CM, Albiger NM. Cyclic Cushing’s syndrome: an overview. Pituitary. 2004;7(4):203–207.
   Google Scholar
• Orth DN. Cushing’s syndrome. N Engl J Med. 1995;332(12):791–803.
   Google Scholar
• Kelly DF. Transsphenoidal surgery for Cushing’s disease: a review of success rates, remission predictors, management of failed surgery, and Nelson’s syndrome. Neurosurg Focus. 2007;23(3):E5.
   PubMedGoogle Scholar
• Bigos ST, Robert F, Pelletier G, Hardy J. Cure of Cushing’s disease by transsphenoidal removal of a microadenoma from a pituitary gland despite a radiographically normal sella turcica. J Clin Endocrinol Metab. 1977;45(6):1251–1260.
   Web of Science ®Google Scholar
• Hardy J. The transsphenoidal surgical approach to the pituitary. Hosp Pract. 1979;14(6):81–89.
   Web of Science ®Google Scholar
• Salassa RM, Laws ER Jr, Carpenter PC, Northcutt RC. Transsphenoidal removal of pituitary microadenoma in Cushing’s disease. Mayo Clin Proc. 1978;53(1):24–28.
   Web of Science ®Google Scholar
• Tyrrell JB, Brooks RM, Fitzgerald PA, Cofoid PB, Forsham PH, Wilson CB. Cushing’s disease. Selective trans-sphenoidal resection of pituitary microadenomas. N Engl J Med. 1978;298(14):753–758.
   PubMed Web of Science ®Google Scholar
• Fomekong E, Maiter D, Grandin C, Raftopoulos C. Outcome of transsphenoidal surgery for Cushing’s disease: a high remission rate in ACTH-secreting macroadenomas. Clin Neurol Neurosurg. 2009;111(5):442–449.
   Web of Science ®Google Scholar
• Shimon I, Ram Z, Cohen ZR, Hadani M. Transsphenoidal surgery for Cushing’s disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery. 2002;51(1):57–62.
   Web of Science ®Google Scholar
• Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF Long-term follow-up results of transsphenoidal surgery for Cushing’s disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf). 2002;56(4):541–551.
   PubMed Web of Science ®Google Scholar
• Chee GH, Mathias DB, James RA, Kendall-Taylor P. Transsphenoidal pituitary surgery in Cushing’s disease: can we predict outcome? Clin Endocrinol (Oxf). 2001;54(5):617–626.
   Web of Science ®Google Scholar
• Netea-Maier RT, van Lindert EJ, den Heijer M, et al. Transsphenoidal pituitary surgery via the endoscopic technique: results in 35 consecutive patients with Cushing’s disease. Eur J Endocrinol. 2006;154(5):675–684.
   Web of Science ®Google Scholar
• Lindsay JR, Oldfield EH, Stratakis CA, Nieman LK. The postoperative basal cortisol and CRH tests for prediction of long-term remission from Cushing’s disease after transsphenoidal surgery. J Clin Endocrinol Metab. 2011;96(7):2057–2064.
   PubMed Web of Science ®Google Scholar
• Esposito F, Dusick J, Cohan P, et al. Clinical review: early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab. 2006;91(1):7–13.
   Web of Science ®Google Scholar
• Chen JC, Amar AP, Choi S, Singer P, Couldwell WT, Weiss MH. Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test. J Neurosurg. 2003;98(5):967–973.
   PubMed Web of Science ®Google Scholar
• Patil CG, Lad SP, Harsh GR, Laws ER Jr, Boakye M. National trends, complications, and outcomes following transsphenoidal surgery for Cushing’s disease from 1993 to 2002. Neurosurg Focus. 2007;23(3):E7.
   Google Scholar
• Barker FG 2nd, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab. 2003;88(10):4709–4719.
   PubMed Web of Science ®Google Scholar
• Locatelli M, Vance ML, Laws ER. Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab. 2005;90(9):5478–5482.
   PubMed Web of Science ®Google Scholar
• Cannavo S, Almoto B, Dall’Asta C, et al. Long-term results of treatment in patients with ACTH-secreting pituitary macroadenomas. Eur J Endocrinol. 2003;149(3):195–200.
   Web of Science ®Google Scholar
• Kemink L, Pieters G, Hermus A, Smals A, Kloppenborg P. Patient’s age is a simple predictive factor for the development of Nelson’s syndrome after total adrenalectomy for Cushing’s disease. J Clin Endocrinol Metab. 1994;79(3):887–889.
   Web of Science ®Google Scholar
• Sonino N, Zielezny M, Fava GA, Fallo F, Boscaro M. Risk factors and long-term outcome in pituitary-dependent Cushing’s disease. J Clin Endocrinol Metab. 1996;81(7):2647–2652.
   Web of Science ®Google Scholar
• Jenkins PJ, Trainer PJ, Plowman PN, et al. The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing’s syndrome. J Clin Endocrinol Metab. 1995;80(1):165–171.
   PubMed Web of Science ®Google Scholar
• Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab. 1999;84(2):440–448.
   Google Scholar
• Kasperlik-Zaluska AA, Nielubowicz J, Wislawski J, et al. Nelson’s syndrome: incidence and prognosis. Clin Endocrinol (Oxf). 1983;19(6):693–698.
   Web of Science ®Google Scholar
• Turrentine FE, Henderson WG, Khuri SF, et al. Adrenalectomy in Veterans Affairs and selected university medical centers: results of the patient safety in surgery study. J Am Coll Surg. 2007;204(6):1273–1283.
   Web of Science ®Google Scholar
• Poulin EC, Schlachta CM, Burpee SE, Pace KT, Mamazza J. Laparoscopic adrenalectomy: pathologic features determine outcome. Can J Surg. 2003;46(5):340–344.
   Web of Science ®Google Scholar
• Smith PW, Turza KC, Carter CO, Vance ML, Laws ER, Hanks JB. Bilateral adrenalectomy for refractory Cushing’s disease: a safe and definitive therapy. J Am Coll Surg. 2009;208(6):1059–1064.
   PubMed Web of Science ®Google Scholar
• Nagesser SK, van Seters AP, Kievit J, Hermans J, Krans HM, van de Velde CJ. Long-term results of total adrenalectomy for Cushing’s disease. World J Surg. 2000;24(1):108–113.
   Web of Science ®Google Scholar
• Valimaki M, Pelkonen R, Porkka L, Sivula A, Kahri A. Long-term results of adrenal surgery in patients with Cushing’s syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxf). 1984;20(2):229–236.
   Web of Science ®Google Scholar
• Sarkar R, Thompson NW, McLeod MK. The role of adrenalectomy in Cushing’s syndrome. Surgery. 1990;108(6):1079–1084.
   Web of Science ®Google Scholar
• Howlett TA, Plowman PN, Wass JA, Rees LH, Jones AE, Besser GM. Megavoltage pituitary irradiation in the management of Cushing’s disease and Nelson’s syndrome: long-term follow-up. Clin Endocrinol (Oxf). 1989;31(3):309–323.
   Web of Science ®Google Scholar
• Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med. 1997;336(3):172–177.
   PubMed Web of Science ®Google Scholar
• Imaki T, Tsushima T, Hizuka N, et al. Postoperative plasma cortisol levels predict long-term outcome in patients with Cushing’s disease and determine which patients should be treated with pituitary irradiation after surgery. Endocr J. 2001;48(1):53–62.
   Web of Science ®Google Scholar
• Vicente A, Estrada J, de la Cuerda C, et al. Results of external pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. Acta Endocrinol (Copenh). 1991;125(5):470–474.
   Google Scholar
• Swords FM, Allan CA, Plowman PN, et al. Stereotactic radiosurgery XVI: a treatment for previously irradiated pituitary adenomas. J Clin Endocrinol Metab. 2003;88(11):5334–5340.
   Web of Science ®Google Scholar
• Alexandraki KI, Grossman AB. The ectopic ACTH syndrome. Rev Endocr Metab Disord. 2010;11(2):117–126.
   PubMed Web of Science ®Google Scholar
• Zografos GN, Markou A, Ageli C, et al. Laparoscopic surgery for adrenal tumors. A retrospective analysis. Hormones (Athens). 2006;5(1):52–56.
   Google Scholar
• Feelders RA, Hofland LJ, de Herder WW. Medical treatment of Cushing’s syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology. 2010;92 Suppl 1:S111–S115.
   Google Scholar
• Arnaldi G, Boscaro M. Pasireotide for the treatment of Cushing’s disease. Expert Opin Investig Drugs. 2010;19(7):889–898.
   PubMed Web of Science ®Google Scholar
• Engelhardt D, Weber MM. Therapy of Cushing’s syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol. 1994;49(4–6):261–267.
   Web of Science ®Google Scholar
• Winquist EW, Laskey J, Crump M, Khamsi F, Shepherd FA. Ketoconazole in the management of paraneoplastic Cushing’s syndrome secondary to ectopic adrenocorticotropin production. J Clin Oncol. 1995;13(1):157–164.
   Web of Science ®Google Scholar
• Patii CG, Hayden M, Katznelson L, Chang SD. Non-surgical management of hormone-secreting pituitary tumors. J Clin Neurosci. 2009;16(8):985–993.
   Web of Science ®Google Scholar
• Sharma ST, Nieman LK. Cushing’s syndrome: all variants, detection, and treatment. Endocrinol Metab Clin North Am. 2011;40(2):379–391.
   PubMed Web of Science ®Google Scholar
• Nieman LK, Ilias I. Evaluation and treatment of Cushing’s syndrome. Am J Med. 2005;118(12):1340–1346.
   PubMed Web of Science ®Google Scholar
• Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M. Prolactinomas, Cushing’s disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord. 2010;10:10.
   PubMed Web of Science ®Google Scholar
• Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease. Eur J Endocrinol. 2008;158(1):91–99.
   PubMed Web of Science ®Google Scholar
• Bademci G. Pitfalls in the management of Cushing’s disease. J Clin Neurosci. 2007;14(5):401–409.
   Web of Science ®Google Scholar
• Liubinas SV, Porto LD, Kaye AH. Management of recurrent Cushing’s disease. J Clin Neurosci. 2011;18(1):7–12.
   PubMed Web of Science ®Google Scholar
• Lekarev O, New MI. Adrenal disease in pregnancy. Best Pract Res Clin Endocrinol Metab. 2011;25(6):959–973.
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Verhelst J, Mahler C, Abs R. Cushing’s syndrome in pregnancy treated by ketaconazole: case report and review of the literature. Gynecol Endocrinol. 1999;13(3):175–182.
   PubMed Web of Science ®Google Scholar
• Yawar A, Zuberi LM, Haque N. Cushing’s disease and pregnancy: case report and literature review. Endocr Pract. 2007;13(3):296–299.
   Google Scholar
• Schimmer BP, Parker KL. Corticotropina, esteroides de la corteza suprarrenal y sus análogos sintéticos, inhibidores de la síntesis y efectos de las hormonas suprarrenales. Goodman and Gilman, Las bases farmacológicas de la terapéutica. Brunton LL, Lazo JS, Parker KL, editors. México: McGraw-Hill; 2007:1587–1612.
   Google Scholar
• Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93(7):2454–2462.
   PubMed Web of Science ®Google Scholar
• Schteingart DE. Drugs in the medical treatment of Cushing’s syndrome. Expert Opin Emerg Drugs. 2009;14(4):661–671.
   PubMed Web of Science ®Google Scholar
• Greening JE, Brain CE, Perry LA, et al. Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing’s disease. Horm Res. 2005;64(3):140–143.
   PubMed Web of Science ®Google Scholar
• Chan LF, Vaidya M, Westphal B, et al. Use of intravenous etomidate to control acute psychosis induced by the hypercortisolaemia in severe paediatric Cushing’s disease. Horm Res Paediatr. 2011;75(6):441–446.
   Web of Science ®Google Scholar
• Albert SG, Ariyan S, Rather A. The effect of etomidate on adrenal function in critical illness: a systematic review. Intensive Care Med. 2011;37(6):901–910.
   Web of Science ®Google Scholar
• Chabner BA, Amrein PC, Druker BJ, et al. Fármacos antineoplásicos. Goodman and Gilman, Las bases farmacológicas de la terapéutica. Brunton LL, Lazo JS, Parker KL, editors. México: McGraw-Hill; 2007: 1315–1403.
   Google Scholar
• Kawai S, Ichikawa Y, Kaburaki J, Yoshida T. 18 years mitotane therapy for intractable Cushing’s disease. Lancet. 1999;354(9182):951.
   Web of Science ®Google Scholar
• Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR- gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002;8(11):1281–1287.
   PubMed Web of Science ®Google Scholar
• Heaney AP, Fernando M, Melmed S. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest. 2003;111(9):1381–1388.
   Web of Science ®Google Scholar
• Ambrosi B, Dall’Asta C, Cannavo S, et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing’s disease. Eur J Endocrinol. 2004;151(2):173–178.
   Web of Science ®Google Scholar
• Pecori Giraldi F, Scaroni C, Arvat E, et al. Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing’s disease. Clin Endocrinol (Oxf). 2006;64(2):219–224.
   PubMed Web of Science ®Google Scholar
• Suri D, Weiss RE. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing’s disease. J Clin Endocrinol Metab. 2005;90(3):1340–1346.
   PubMed Web of Science ®Google Scholar
• Emery MN, Leontiou C, Bonner SE, et al. PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor. Clin Endocrinol (Oxf). 2006;65(3):389–395.
   Web of Science ®Google Scholar
• Gil-Cárdenas A, Herrera MF, Díaz-Polanco A, Rios JM, Pantoja JP Nelson’s syndrome after bilateral adrenalectomy for Cushing’s disease. Surgery. 2007;141(2):147–152.
   Web of Science ®Google Scholar
• Alexandraki KI, Grossman AB. Pituitary-targeted medical therapy of Cushing’s disease. Expert Opin Investig Drugs. 2008;17(5):669–677.
   PubMed Web of Science ®Google Scholar
• Casulari LA, Naves LA, Mello PA, Pereira Neto A, Papadia C. Nelson’s syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res. 2004;62(6):300–305.
   PubMedGoogle Scholar
• Arnaldi G, Boscaro M. Pasireotide for the treatment of Cushing’s disease. Expert Opin Investig Drugs. 2010;19(7):889–898.
   PubMed Web of Science ®Google Scholar
• Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab. 2009;94(2):654–661.
   PubMed Web of Science ®Google Scholar
• Batista DL, Zhang X, Gejman R, et al. The effects of S0M230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab. 2006;91(11):4482–4488.
   PubMed Web of Science ®Google Scholar
• de Bruin C, Pereira AM, Feelders RA, et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab. 2009;94(4):1118–1124.
   PubMed Web of Science ®Google Scholar
• Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary- dependent Cushing’s disease with multireceptor ligand somatostatin analog pasireotide (S0M230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94(1):115–122.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhu F, Ma X, et al. The Therapeutic Target Database: an internet resource for the primary targets of approved, clinical trial and experimental drugs. Expert Opin Ther Targets. 2011;15(8):903–912.
   PubMed Web of Science ®Google Scholar
• Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N Engl J Med. 2010;362(19):1846–1848.
   PubMed Web of Science ®Google Scholar
• de Bruin C, Hofland LJ, Nieman LK, et al. Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing’s syndrome due to ectopic adrenocorticotropin secretion. J Clin Endocrinol Metab. 2012;97(2):455–462.
   PubMed Web of Science ®Google Scholar
• van der Hoek J, Waaijers M, van Koetsveld PM, et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab. 2005;289(2):E278-E287.
   PubMed Web of Science ®Google Scholar
• Lupp A, Hunder A, Petrich A, Nagel F, Doll C, Schultz S. Reassessment of sst(5) somatostatin receptor expression in normal and neoplastic human tissues using de novel rabbit monoclonal antibody UMB-4. Neuroendocrinology. 2011;94(3):255–264.
   Web of Science ®Google Scholar
• Colao A, Lombardi G, Annunziato L. Cabergoline. Expert Opin Pharmacother. 2000;1(3):555–574.
   PubMedGoogle Scholar
• Paez-Pereda M, Arzt E, Stalla GK. Cushing’s syndrome: drug targets and therapeutic options. Expert Opin Ther Pat. 2002;12(10):1537–1546.
   Web of Science ®Google Scholar
• Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing’s disease. Eur J Endocrinol. 2010;163(5):709–716.
   PubMed Web of Science ®Google Scholar
• Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccesfully treated by surgery. J Clin Endocrinol Metab. 2009;94(1):223–230.
   PubMed Web of Science ®Google Scholar
• Lila AR, Gopal RA, Acharya SV et al. Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract. 2010;16(6):968–976.
   Web of Science ®Google Scholar
• Vilar L, Naves LA, Azevedo MF, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease. Pituitary. 2010;13(2):123–129.
   PubMed Web of Science ®Google Scholar
• Im A, Appleman LJ. Mifepristone: pharmacology and clinical impact in reproductive medicine, endocrinology and oncology. Expert Opin Pharmacother. 2010;11(3):481–488.
   Web of Science ®Google Scholar
• Spitz IM. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids. 2003;68(10–13):981–993.
   Web of Science ®Google Scholar
• Benagiano G, Bastianelli C, Farris M. Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. Expert Opin Pharmacother. 2008;9(14):2487–2496.
   PubMed Web of Science ®Google Scholar
• Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing’s syndrome. Eur J Endocrinol. 2007;157(5):561–569.
   PubMed Web of Science ®Google Scholar
• Peverelli E, Olgiati L, Locatelli M, et al. The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activatin ERK1/2 and p38 pathways. Cancer Lett. 2010;288(2):170–176.
   Web of Science ®Google Scholar
• Drutel A, Caron P, Archambeaud F. New medical treatments in pituitary adenomas. Ann Endocrinol (Paris). 2008;69 Suppl 1:S16-S28.
   Google Scholar